Up next

Autoplay

Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors

0 Views • 07/09/23
Share
Embed
administrator
administrator
Subscribers
0

From ASCO 2011 -- A discussion with Prof. Eric Raymond on his poster presented at ASCO in June 2011 titled "Updated Overall Survival (OS) and Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) of Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors (NET)"

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay